Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-05-01
2007-05-01
Carlson, Karen Cochrane (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S385000
Reexamination Certificate
active
10747580
ABSTRACT:
The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.
REFERENCES:
patent: 4001200 (1977-01-01), Bonsen et al.
patent: 4001401 (1977-01-01), Bonsen et al.
patent: 4703008 (1987-10-01), Lin
patent: 4810643 (1989-03-01), Souza
patent: 4868119 (1989-09-01), Clark et al.
patent: 5028588 (1991-07-01), Hoffman et al.
patent: 5032676 (1991-07-01), Deeley et al.
patent: 5428007 (1995-06-01), Fischer et al.
patent: 5545727 (1996-08-01), Hoffman et al.
patent: 5585484 (1996-12-01), Acharya et al.
patent: 5614490 (1997-03-01), Przybelski
patent: 5631219 (1997-05-01), Rosenthal et al.
patent: 5658879 (1997-08-01), Nho
patent: 5679638 (1997-10-01), Teicher et al.
patent: 5750725 (1998-05-01), Acharya et al.
patent: 5844088 (1998-12-01), Hoffman et al.
patent: 5844089 (1998-12-01), Hoffman et al.
patent: 5844090 (1998-12-01), Anderson et al.
patent: 5914391 (1999-06-01), Gerber et al.
patent: 6017943 (2000-01-01), Acharya et al.
patent: 6048967 (2000-04-01), Hsia
patent: 6670323 (2003-12-01), Looker et al.
patent: 0 561 245 (1993-09-01), None
patent: WO 88/06161 (1988-08-01), None
patent: WO 91/05795 (1991-05-01), None
patent: WO 95/14038 (1995-05-01), None
patent: WO 95/24213 (1995-09-01), None
patent: WO 98/17289 (1998-04-01), None
patent: WO 98/50430 (1998-11-01), None
Conklin, et al. “Effects of Recombinant Human Hemoglobin on Motor Functions of the Opossum Esophagus.” The Journal of Pharmacology and Experimental Therapeutice, 1995, vol. 273, No. 2, pp. 762-767.
Conover, et al., “The Influence of Polyethylene Glycol Conjugation on Bovine Hemoglobin's Intrinsic Effect on the Gastrointestinal System of the Rat.” Life Sciences, 1996, vol. 59, No. 22, pp. 1861-1869.
Cupane et al. “Modification of α-chain Heme Pocket Polarity by Val(E11) Thr Substitution has Different Effects on the Steric, Dynamic, and Functional Properties of Human Recombinant Hemoglobin.” The Journal of Biological Chemistry, 1997, pp. 26271-26278, vol. 272, No. 42.
Deligné, P., “Quoi de neuf en 1990 en matiére de substituts de sang? I. Améliorations des solutions d' heémoglobin modifiée et hémoglobines issues de la bio-ingénierie et du génie génétique.” Urgences, 1990, pp. 76-85, vol. 9.
Doyle, et al., “Oxidation of Nitrogen Oxides by Bound Dioxygen in Hemoproteins.” Journal of Inorganic Biochemistry, 1981, pp. 351-358, vol. 14, Elsevier North Holland, Inc., New York.
Eich, et al., “Mechanism of NO-Induced Oxidation of Myoglobin and Hemoglobin.” Biochemistry, 1996, vol. 35, pp. 6676-6983.
Feola, et al. “Clinical Trial of a Hemoglobin Based Blood Substitute in Patients with Sickle Cell Anemia”. Surgery, Gynecology & Obstetrics, 1992, vol. 174, pp. 379-386.
Gould et al., “Clinical Development of Human Polymerized Hemoglobin as a Blood Substitute.” World Journal of Surgery, 1996, vol. 20, No. 9, pp. 1200-1207.
Hartman et al., “Reduced Nitric Oxide Reactivity of a New Recombinant Human Hemoglobin Attenuates Gastric Dysmotility.” European Journal of Pharmacology, 1998, pp. 175-178, vol. 363.
Huisman T., “Recombinant Hemoglobin Variants”, Hemoblobin, 1998, pp. 99-112, vol. 22, No. 2.
Looker, et al., “A Human Recombinant Haemoglobin Designed for use as a Blood Substitute.” Letters to Nature, 1992, vol. 356, pp. 258-260.
Moore, et al., “Cooperativity in the Dissociation of Nitric Oxide From Hemoglobin.” The Journal of Biological Chemistry, 1976, pp. 2788-2794, vol. 251, No. 9, Waverly Press, Inc., Baltimore.
Reddy, et al., “Role of β87 Thr in the β6 Val Acceptor Site during Deoxy Hb S Polymerization.” Biochemistry, 1997, vol. 36, pp. 15992-15998.
Remy et al, “Apports et perspectives des dérivé de l'hémoglobine”. Schweiz Med Wochenschr, 1997, pp. 1088-1096, vol. 127.
Tsuchida, E., “Introduction: Overview and Perspectives”. Artificial Red Cells: Materials, Performances and Clinical Study as Blood Substitutes, Liely, New York, NY, pp. 1-20, 1995.
Viele, et al., “Recombinant Human Hemoglobin Does not Affect Renal Function in Humans: Analysis of Safety and Pharmacokinetics.” Anesthesiology, 1997, vol. 86, No. 4, pp. 848-858.
Walder, et al. “Development of Antisickling Compounds that Chemically Modify Hemoglobin S Specifically within the 2,3-Diphosphoglycerate Binding Site”. J. Mol. Biol., 1980, vol. 141, pp. 195-216, Academic Press, Inc. (London) Ltd.
Apostol Izydor Z.
Brucker Eric A.
Burhop Kenneth E.
Doyle Michael P.
Foster David L.
Baxter Healthcare S.A.
Baxter International Inc.
Carlson Karen Cochrane
Senniger Powers
LandOfFree
Reduced side-effect hemoglobin compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reduced side-effect hemoglobin compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reduced side-effect hemoglobin compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3735144